» Articles » PMID: 35978433

Immune Checkpoint Modulators in Cancer Immunotherapy: Recent Advances and Emerging Concepts

Overview
Journal J Hematol Oncol
Publisher Biomed Central
Specialties Hematology
Oncology
Date 2022 Aug 17
PMID 35978433
Authors
Affiliations
Soon will be listed here.
Abstract

The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of checkpoint molecules: anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on several cancer types achieved satisfying results. However, there are still quite a lot of patients suffering from severe side effects and ineffective treatment outcomes. Although the current ICI therapy is far from satisfying, a series of novel immune checkpoint molecules with remarkable preclinical and clinical benefits are being widely investigated, like the V-domain Ig suppressor of T cell activation (VISTA), which can also be called PD-1 homolog (PD-1H), and ectonucleotidases: CD39, CD73, and CD38, which belong to the ribosyl cyclase family, etc. In this review, we systematically summarized and discussed these molecules' biological structures, molecular features, and the corresponding targeted drugs, aiming to help the in-depth understanding of immune checkpoint molecules and promote the clinical practice of ICI therapy.

Citing Articles

Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.

Jiang K, Liu M, Zhao X, Wang S, Ling Y, Qiao L Eur J Clin Pharmacol. 2025; .

PMID: 40080137 DOI: 10.1007/s00228-025-03820-y.


Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline.

Alonso-Ron C, Vethencourt A, Gonzalez-Suarez E, Oruezabal R Cancers (Basel). 2025; 17(4).

PMID: 40002228 PMC: 11853049. DOI: 10.3390/cancers17040633.


Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report.

Cherukuri P, Tayyeb M, Gaddameedi S, Du D, Meghal T World J Clin Oncol. 2025; 16(2):97823.

PMID: 39995559 PMC: 11686565. DOI: 10.5306/wjco.v16.i2.97823.


Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Passariello M, Manna L, Rapuano Lembo R, Yoshioka A, Inoue T, Kajiwara K Cell Death Discov. 2025; 11(1):58.

PMID: 39929828 PMC: 11811032. DOI: 10.1038/s41420-025-02329-8.


Beyond checkpoint inhibitors: the three generations of immunotherapy.

Schaub J, Tang S Clin Exp Med. 2025; 25(1):43.

PMID: 39888507 PMC: 11785663. DOI: 10.1007/s10238-024-01546-2.


References
1.
Lim J, Gerber S, Murphy S, Lord E . Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother. 2013; 63(3):259-71. PMC: 3944132. DOI: 10.1007/s00262-013-1506-7. View

2.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

3.
Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

4.
Tsai R, Discher D . Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008; 180(5):989-1003. PMC: 2265407. DOI: 10.1083/jcb.200708043. View

5.
McEarchern J, Smith L, McDonagh C, Klussman K, Gordon K, Morris-Tilden C . Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res. 2008; 14(23):7763-72. DOI: 10.1158/1078-0432.CCR-08-0493. View